Media Coverage of Psilocybin Outpaces the Science, a New Systematic Review Finds
A systematic review in JAMA Network Open (Kim Madden, lead author, with Breanne Flood, Imad Kashir, Rayan Ahmad, Hiba Ali, Rotem Petranker, James MacKillop, and senior author Anthony Adili) compared 70 psilocybin trial publications (2014–2024) against 172 news articles covering them (2014–2025), reported by PsyPost's Eric W. Dolan on Oct 27.
The gap isn't really about whether psilocybin "works" — 70% of trials concluded benefit on their primary outcome, and 73% of news articles made a positive claim, which looks close. It's in the framing and the silences around that number. Trial authors routinely flagged limitations and small samples (93% of the 70 papers had fewer than 100 participants); news coverage largely didn't, with 71% of articles striking a favorable tone outright. Coverage also extrapolated well past what's been tested: PTSD appeared in 43% of articles despite zero eligible trials testing it, anxiety in 42% of articles against just 4 trials, and anorexia/eating disorders in 10% of articles against a single trial. Safety got the least attention on either side, but the asymmetry held: 44% of trials reported safety outcomes versus just 30% of news articles mentioning adverse effects at all, and 83% of articles never mentioned dosing.
Adili's own framing to PsyPost: "there is a disconnect between media publications and the hard science," and "media articles may bias positive results without discussing safety concerns." It's a fair prompt for any outlet writing about this compound, including ours — our own encyclopedia entry and trials tracker are the two places we try to keep the trial-stage caveats attached to any psilocybin claim we make.